Daromun

{
  "id": "MLC-T-ONC-012927",
  "term": "Daromun",
  "field": "Oncology and biomedicine",
  "definition": "A combination of darleukin (L19-IL2), an immunocytokine consisting of the recombinant form of interleukin-2 (IL-2), fused to a human single-chain variable fragment (scFv) directed against the extra-domain B (ED-B) of fibronectin (L19), and fibromun (L19-TNFalpha), an immunocytokine consisting of human tumor necrosis factor alpha (TNFalpha) fused to a human scFv antibody fragment directed against the ED-B of L19, with potential antineoplastic and immunostimulating activities. Upon administration, the L-19 moieties of each immunocytokine bind to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. In turn, the IL-2 and TNF-alpha moieties of darleukin and fibromun, respectively, may locally induce an immune response against ED-B fibronectin-expressing tumor cells. ED-B is predominantly expressed during angiogenesis and tumor growth.",
  "synonyms": [
    "darleukin and fibromun",
    "L19-IL2 and L19-TNF-alpha",
    "L19IL2/L19TNF",
    "L19-IL2/L19-TNF-alpha",
    "darleukin/fibromun"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/daromun/"
}